Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study

Figures & data

Table 1 Interview schedule

Could you tell me about your experience of taking the medicine for chronic myeloid leukemia?

What problems or difficulties have you had while taking this medicine?

How do you cope with the problems or difficulties while taking this medicine?

What are your worries about taking this medicine?

Can you describe to me in detail how you take this medicine?

What is your opinion about taking this medicine?

What do you think needs to be improved?

Is there anything else you would like to discuss about the problems or difficulties while taking this medicine?

Table 2 Characteristics of participants

ID	Gender	Age, years	Ethnicity	Education	Marital status	Employment	Duration of chronic myeloid leukemia	Disease phase at diagnosis	Tyrosine kinase inhibitor	Number of concomitant medications	Bcr-Abla
P1	Male	39	Indian	Secondary	Single	Unemployed	9 years	Chronic	Imatinib	2	Below the limit of detection
P2	Male	37	Chinese	Secondary	Married	Employed	6 years	Chronic	Imatinib	0	0.3011%
P3	Female	64	Malay	Secondary	Married	Retired	4 years	Chronic	Imatinib	0	0.0114%
P4	Male	54	Malay	Secondary	Married	Retired	6 years	Chronic	Nilotinib	0	46.0145%
P5	Female	62	Malay	Secondary	Married	Homemaker	12 years	Chronic	Nilotinib	3	4.5100%
P6	Female	66	Malay	Secondary	Divorced	Retired	3 months	Accelerated	Nilotinib	6	Not available
P7	Male	43	Malay	Tertiary	Married	Employed	5 years	Chronic	Imatinib	0	0.0501%
P8	Female	67	Chinese	Secondary	Married	Retired	4 years	Chronic	Imatinib	1	0.0362%
P9	Male	30	Malay	Secondary	Married	Employed	14 years	Chronic	Nilotinib	0	3.5377%
P10	Female	55	Chinese	Secondary	Married	Homemaker	2 years	Chronic	Imatinib	0	0.0201%
P11	Male	32	Malay	Tertiary	Single	Employed	8 months	Chronic	Imatinib	4	Not available
P12	Male	26	Chinese	Tertiary	Single	Employed	3 years	Chronic	Imatinib	0	Not available (white blood cell count in 10^9 per liter =52.96)
P13	Female	52	Indian	Primary	Married	Homemaker	11 years	Chronic	Imatinib	1	0.0551%
P14	Male	34	Indian	Tertiary	Single	Employed	16 years	Chronic	Imatinib	0	0.0420%
P15	Female	38	Malay	Tertiary	Married	Employed	8 years	Accelerated	Imatinib	0	0.0485%
P16	Female	61	Malay	Primary	Married	Homemaker	6 years	Accelerated	Imatinib	5	Not monitored (progress to acute myeloid leukemia)
P17	Female	27	Malay	Tertiary	Single	Employed	4 years	Chronic	Imatinib	0	0.1720%
P18	Male	35	Malay	Tertiary	Married	Employed	3 years	Chronic	Nilotinib	0	Not monitored

Note:

a denotes latest reading at the time of interview in international scale.

Figure 1 Themes of medication-related issues affecting chronic myeloid leukemia patients’ adherence to tyrosine kinase inhibitors (TKIs).